Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey
Takahiro Miyazaki(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Paul Sims(Nektar Therapeutics (United States)), Murali K. Addepalli(Nektar Therapeutics (United States)), Peiwen Kuo(Nektar Therapeutics (United States)), Mekhala Maiti(Nektar Therapeutics (United States)), Loui Madakamutil(Nektar Therapeutics (United States)), Mario Q. Marcondes(Nektar Therapeutics (United States)), Palakshi Obalapur, Ping Zhang(Ningbo University), Werner Rubas(University of California, San Francisco)
Cited by 4
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403